Ramy Farid Biography and Net Worth

Ramy Farid, Ph.D., is president, chief executive officer, and a member of the board of directors. He joined Schrödinger in 2002 and helped advance the company’s computational platform and drug discovery portfolio while assuming positions of increasing responsibility before becoming CEO in 2017. Dr. Farid has played a key role in implementing major strategic initiatives, including more than 40 research collaborations and joint ventures, and led the company through its initial public offering in 2020. Dr. Farid currently serves on the board of directors of Ajax Therapeutics, Inc., a private biotechnology company (and collaboration partner of Schrödinger), and Vir Biotechnology, a U.S. publicly traded biopharmaceutical company. Previously, he served on the boards of directors of Structure Therapeutics, a U.S. publicly traded biopharmaceutical company, Morphic Therapeutic, Inc., a U.S. publicly traded biopharmaceutical company that was acquired by Lilly in 2024, Nimbus Therapeutics, a private biotechnology company (which he helped found in 2009), and Oak Hill Bio Ltd., a private biotechnology company. Dr. Farid began his career in academia and was an assistant professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his doctoral degree in chemistry from Caltech. He is an author on 100 peer reviewed publications.